Enanta Pharma (ENTA) Misses Q3 EPS by 1c

Enanta Pharma (NASDAQ: ENTA) reported Q3 EPS of $0.97, $0.01 worse than the analyst estimate of $0.98. Revenue for the quarter came in at $57.3 million versus the consensus estimate of $56.93 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Ross Stores raises 2026 outlook after strong second-quarter results
• LSI Industries (LYTS) Tops Q4 EPS by 3c, Beats on Revenue